

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Jayex Healthcare Limited
ABN 15 119 122 477

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Boyd
Date of last notice	10 May 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Michael Boyd has a relevant interest, in accordance with section 608(3)(b) of the Corporations Act 2001 (Cth), in the 74,981,855 securities held by Covenant Holdings (WA) Pty Ltd. through his position as controlling Shareholder of that company. Michael Boyd has a relevant interest, in accordance with section 608(3)(b) of the Corporations Act 2001 (Cth), in the 6,505,530 securities held by New Medical Enterprises Pty Ltd through his position as controlling Shareholder of that company.
Date of change	10 – 13 May 2016
No. of securities held prior to change	81,327,335

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Class	Fully paid ordinary shares
Number acquired	160,050
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$0.19 - \$0.20 per share, totalling \$31,351
No. of securities held after change	81,487,385
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market acquisitions

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	2 May 2016

+ See chapter 19 for defined terms.